74725-06-7

Basic information

• Product Name: 2,5-Bis-broMoMethyl-benzoic acid Methyl ester
• Synonyms: 2,5-Bis-broMoMethyl-benzoic acid Methyl ester;Methyl 2,5-bis(broMoMethyl)benzoate
• CAS NO: 74725-06-7
• Molecular Formula: C₁₀H₁₀Br₂O₂
• Molecular Weight: 307.96662
• Mol File: 74725-06-7.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,5-Bis-broMoMethyl-benzoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Bis-broMoMethyl-benzoic acid Methyl ester(74725-06-7)
• EPA Substance Registry System: 2,5-Bis-broMoMethyl-benzoic acid Methyl ester(74725-06-7)

Safety Data

• Hazardous Substances Data: 74725-06-7(Hazardous Substances Data)

Upstream product

• 128-08-5 N-Bromosuccinimide 
• 13730-55-7 methyl 2,5-dimethylbenzoate 
• 186581-53-3 diazomethane 
• 148692-70-0 2,5-bis(bromomethyl)benzoic acid 
• 22328-43-4 2,5-dimethylbenzoyl chloride 
• 610-72-0 2,5-dimethylbenzoic acid 

Downstream Products

• 452978-22-2 methyl 2,5-bis(acetoxymethyl)benzoate 
• 452978-42-6 1-Oxo-1,3-dihydroisobenzofuran-6-carbaldehyde 

Relevant articles and documents

Novel PTP1B enzyme inhibitor, preparation method and applications thereof

The present invention provides a novel PTP1B enzyme inhibitor, a preparation method and applications thereof, and particularly discloses a class of bis 2-substituted ethylene sulfonate compounds and a preparation method thereof, and uses of the bis 2-substituted ethylene sulfonate compounds as the PTP1B enzyme activity inhibitor. According to the present invention, the prepared novel compound has good PTP1B enzyme activity inhibition effect, and has the application value in preparation of drugs for treatment and prevention of diabetes and obesity.

New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: Synthesis, anti-HIV-1 evaluation and binding affinities

CXCR4 is a target of growing interest for the development of new therapeutic drugs and imaging agents as its role in multiple disease states has been demonstrated. AMD3100, a CXCR4 chemokine receptor antagonist that is in current clinical use as a haematopoietic stem cell mobilising drug, has been widely studied for its anti-HIV properties, potential to inhibit metastatic spread of certain cancers and, more recently, its ability to chelate radiometals for nuclear imaging. In this study, AMD3100 is functionalised on the phenyl moiety to investigate the influence of the structural modification on the anti-HIV-1 properties and receptor affinity in competition with anti-CXCR4 monoclonal antibodies and the natural ligand for CXCR4, CXCL12. The effect of complexation of nickel(ii) in the cyclam cavities has been investigated. Two amino derivatives were obtained and are suitable intermediates for conjugation reactions to obtain CXCR4 molecular imaging agents. A fluorescent probe (BODIPY) and a precursor for 18F (positron emitting isotope) radiolabelling were conjugated to validate this route to new CXCR4 imaging agents.

OXYGEN SCAVENGING MOLECULES, ARTICLES CONTAINING SAME, AND METHODS OF THEIR USE

The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.